Spero Therapeutics, Inc. (SPRO) Revenue History
Annual and quarterly revenue from 2015 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
SPRO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
SPRO Revenue Analysis (2015–2024)
As of March 1, 2026, Spero Therapeutics, Inc. (SPRO) generated trailing twelve-month (TTM) revenue of $35.8 million, reflecting significant decline in growth of -77.4% year-over-year. The most recent quarter (Q3 2025) recorded $3.0 million in revenue, down 74.2% sequentially.
Looking at the longer-term picture, SPRO's 5-year compound annual growth rate (CAGR) stands at +21.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $103.8 million in 2023.
Revenue diversification analysis shows SPRO's business is primarily driven by Collaboration Revenue Related Party (56%), Grant Revenue (43%), and Collaboration Revenue (1%). With over half of revenue concentrated in Collaboration Revenue Related Party, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY), SPRO has underperformed the peer group in terms of revenue growth. Compare SPRO vs BNTX →
Peer Comparison
Compare SPRO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SPROCurrent | $36M | -77.4% | +21.5% | -152.9% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $48.0M | -53.8% | $-48,780,000 | -101.7% | $-73,361,000 | -152.9% |
| 2023 | $103.8M | +113.6% | $52.3M | 50.4% | $21.5M | 20.7% |
| 2022 | $48.6M | +1482.4% | $48.6M | 100.0% | $-42,197,000 | -86.9% |
| 2021 | $3.1M | -67.1% | $3.1M | 100.0% | $-87,971,000 | -2865.5% |
| 2020 | $9.3M | -48.6% | $-57,673,000 | -618.1% | $-79,113,000 | -847.9% |
| 2019 | $18.1M | +357.6% | $-47,628,000 | -262.5% | $-63,216,000 | -348.4% |
| 2018 | $4.0M | +100.4% | $-29,919,000 | -754.4% | $-42,806,000 | -1079.3% |
| 2017 | $2.0M | +490.7% | $-30,890,000 | -1560.9% | $-41,730,000 | -2108.6% |
| 2016 | $335K | - | $-25,998,000 | -7760.6% | $-33,221,000 | -9916.7% |
| 2015 | $0 | - | $-11,000 | - | $-13,327,000 | - |
See SPRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SPRO vs AGIO
See how SPRO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SPRO's revenue growth accelerating or slowing?
SPRO revenue declined -77.4% year-over-year, contrasting with the 5-year CAGR of +21.5%. TTM revenue fell to $36M. This reverses the prior growth trend.
What is SPRO's long-term revenue growth rate?
Spero Therapeutics, Inc.'s 5-year revenue CAGR of +21.5% reflects the variable expansion pattern. Current YoY growth of -77.4% is below this long-term average.
How is SPRO's revenue distributed by segment?
SPRO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2024 are available for download. Segment mix reveals concentration and diversification trends.